The Revolutionizing Atopic Dermatitis meeting supports the dissemination of knowledge that will advance the field of dermatology and will improve the care of patients with skin disease.
Dr Andy Blauvelt: Drug Approval, Accessibility Challenges in Treating Patients With AD
Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses challenges many physicians face in getting approved for the most effective drugs to treat patients with atopic dermatitis (AD).
What You May Have Missed at RAD 2023
The Revolutionizing Atopic Dermatitis (RAD) meeting took place April 29 through May 1 in Washington, DC, with The American Journal of Managed Care® there to cover the meeting. Some of the top news you may have missed is right below.
Disparities in AD Treatment: What Can Be Done?
Reducing disparities in the treatment of atopic dermatitis (AD) was the focus of a session of the final day of the Revolutionizing Atopic Dermatitis 2023 conference.
Dr Andy Blauvelt on Selecting the Right Patient for Systemic Therapy or Biologics to Treat AD
Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).
Dr Larry Eichenfield: A Changing Therapy Landscape Provides More Options for Infants With AD
Larry Eichenfield, MD, professor of dermatology and pediatrics and vice chair of the Department of Dermatology at the University of California San Diego School of Medicine and chief of pediatric and adolescent dermatology at Rady Children's Hospital San Diego, discusses the use of different treatments and biologics for atopic dermatitis (AD) in infants, which he presented at the Revolutionizing Atopic Dermatitis conference.
Panel Focuses on Burgeoning Therapies in Atopic Dermatitis
A panel held at Revolutionizing Atopic Dermatitis 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.
Dr Melinda Gooderham Discusses Emerging Therapies in Atopic Dermatitis
Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.
Dr Robert Sidbury: How to Treat Facial Atopic Dermatitis in Infants
Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses treatment approaches for atopic dermatitis of the face in infancy, which he presented at the Revolutionizing Atopic Dermatitis conference.
Symposium Highlights New Research on JAK, PDE-4 Inhibitors
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.
Posters Show Ruxolitinib Cream to Be Both Effective and Safe for Treating AD
In posters presented at the Revolutionizing Atopic Dermatitis conference, ruxolitinib cream was found to be both safe and effective in treating atopic dermatitis (AD).
Dr Jonathan Silverberg Previews the Revolutionizing Atopic Dermatitis Meeting
Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research and patch testing at the George Washington University School of Medicine and Health Sciences, and chair of the Revolutionizing Atopic Dermatitis (RAD) conference, discusses some of the symposia and events at this year's conference that he is looking forward to the most.
Revolutionizing Atopic Dermatitis Conference Promises New Ways to Learn About AD
The Revolutionizing Atopic Dermatitis conference, set to begin on April 29 in Washington, DC, promises to offer symposia on emerging therapies and new insights into treating atopic dermatitis (AD).
2 Clarke Drive Cranbury, NJ 08512